10-K: AtriCure Reports Strong 2025 Revenue Growth, Net Loss Narrows

AtriCure, Inc. announced its 2025 annual results, reporting a 14.9% increase in worldwide revenue to $534.5 million, driven by strong adoption of pain management, open ablation, and appendage management products, while net loss significantly narrowed to $11.4 million.

Summary

• Worldwide revenue increased 14.9% to $534,528 thousand in 2025 from $465,307 thousand in 2024.
• Net loss significantly narrowed to $11,448 thousand in 2025 from $44,698 thousand in 2024.
• Gross profit increased to $400,779 thousand (75.0% gross margin) in 2025 from $347,524 thousand (74.7% gross margin) in 2024.
• Open ablation revenue grew 16.3% to $143,847 thousand, pain management revenue grew 32.5% to $81,923 thousand, and appendage management revenue grew 17.5% to $178,127 thousand.
• Minimally invasive ablation sales declined 31.2% to $31,475 thousand, attributed to physicians adopting Pulsed Field Ablation (PFA) catheters.
• International revenue increased 20.2% (17.5% on a constant currency basis) to $99,156 thousand.
• Research and development expenses increased 3.2% to $99,209 thousand, primarily due to headcount growth and clinical trial activities, partially offset by a $6,000 thousand decrease in PFA co-development payments.
• Selling, general and administrative expenses increased 6.7% to $311,017 thousand, mainly due to headcount growth and higher variable and share-based compensation.
• Cash and cash equivalents were $167,428 thousand as of December 31, 2025, with unused borrowing capacity of approximately $61,885 thousand under the asset-backed credit agreement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting robust revenue growth and a substantial reduction in net losses, alongside significant product innovation and clinical trial progress. However, the ongoing net losses and a material legal proceeding introduce a degree of caution.

Positives

• Worldwide revenue grew by 14.9% to $534,528 thousand in 2025.
• Net loss significantly narrowed to $11,448 thousand in 2025, a substantial improvement from $44,698 thousand in 2024.
• Gross margin improved by 29 basis points to 75.0% in 2025, driven by a more favorable product mix.
• Strong growth was observed in open ablation (16.3%), pain management (32.5%), and appendage management (17.5%) product lines.
• Successful product launches include the AtriClip PRO-Mini LAA Exclusion System, cryoICE cryoXT probe for amputation pain, and cryoSPHERE MAX probe.
• First-in-human treatments were successfully executed using a novel dual energy platform integrating Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA).
• Trial enrollment for the LeAAPS IDE clinical trial was completed with 6,573 patients across 139 centers globally.
• The BoxX-NoAF IDE trial initiated its first patient enrollment, expanding the addressable market for concomitant ablation and LAA management to non-Afib patients.
• The company supported the publication of 13 articles and 15 congress abstracts featuring clinical studies in 2025.
• New and innovative physician training methods, such as virtual proctoring and observerships, were launched.
• Employee voluntary turnover rate remained consistently at or below 10%, outperforming the medical device industry average.
• AtriCure was recognized as a Top Workplace ten times in the past eleven years and a Great Place to Work internationally for four consecutive years.
• The Credit Agreement was extended by three years to January 9, 2029, with reduced interest rates and the removal of the minimum utilization financial covenant, enhancing financial flexibility.

Negatives

• The company continues to report net losses, with an accumulated deficit of $413,203 thousand as of December 31, 2025.
• Minimally invasive ablation sales declined by 31.2% due to physicians adopting PFA catheters, indicating competitive pressure in this segment.
• Research and development expenses increased by 3.2%, driven by headcount growth and clinical trial activities, despite a decrease in PFA co-development payments.
• Selling, general and administrative expenses increased by 6.7%, primarily due to headcount growth and higher compensation.
• A legal complaint was filed by former SentreHEART securityholders, seeking up to $260,000 thousand in damages for alleged breach of contract related to the LARIAT System's PMA approval.

Risks

• Failure to achieve widespread market acceptance domestically for products may harm operating results.
• Competition from existing and new products and procedures may decrease market share and cause revenue to decline.
• Clinical data generated regarding products may not be positive, or clinical trials may not satisfy regulatory requirements.
• Reliance on independent distributors in some international markets could adversely impact sales.
• A prolonged downturn in macroeconomic conditions may materially and adversely affect the business.
• Government and private payors may contain or reduce healthcare spending, including reimbursement for procedures that utilize products.
• Adverse changes in governmental and third-party payors' policies toward coverage and reimbursement for surgical procedures would harm the ability to promote and sell products.
• Unfavorable publicity relating to the business or industry could negatively impact operations or stock price.
• Reliance upon single and limited source third-party suppliers and service providers could harm the business if they cannot provide materials or perform services in a timely manner.
• Highly centralized manufacturing operations mean disruption at facilities could increase expenses and decrease revenue.
• Failure to properly manage anticipated growth could cause the business to suffer.
• Inability to retain skilled and experienced officers and other employees, or recruit, hire, train, and integrate sufficient additional qualified personnel, may impair the business.
• Disruptions of critical information systems or material breaches in the security of systems could harm the business, customer relations, and financial condition.
• Insurance may not cover indemnification obligations and other liabilities associated with operations.
• Substantial penalties could be faced if federal, state, and foreign regulations are not fully complied with.
• Fines, injunctions, and penalties may be imposed for failure to comply with FDA regulations.
• Inability to promote products for unapproved uses (Afib, stroke prevention, POAF reduction) without additional FDA approval, with potential fines for off-label promotion.
• Modifications to products may require new clearances or approvals by FDA, potentially resulting in recalls.
• Product liability claims may arise from injuries or other adverse events related to product use.
• Intellectual property rights may not provide meaningful commercial protection for products.
• Litigation and administrative proceedings over patent and other intellectual property rights are common in the industry and could incur substantial costs.
• Various regulatory and other risks related to selling products internationally could harm revenue.
• Changes in United States and international trade policies may adversely impact business and operating results.
• Any allegation or determination of wrongdoing under the Foreign Corrupt Practices Act or other anti-corruption laws could have a material adverse effect.
• The use of artificial intelligence technology by employees or business partners could result in misuse or loss of proprietary information, violation of laws, or damage to reputation.
• Quarterly financial results are likely to fluctuate significantly due to uncertain adoption rates.
• The company has a history of net losses and may never become profitable.
• Governmental authorities may challenge intercompany transfer pricing policies or change laws, increasing the effective tax rate.
• Goodwill may become impaired, which could adversely affect financial performance.
• Inventory-related charges may result from inaccurate forecasting or estimates of product life cycles.
• Credit risk exists from accounts receivable, including sales into countries experiencing economic turmoil.
• Inability to comply with the covenants of the Credit Agreement.
• Failure to meet publicly announced guidance about the business could cause a decline in stock price.
• Securities analysts may discontinue coverage or issue negative reports, negatively impacting the market price of common stock.
• The common stock may experience extreme fluctuations in price and trading volume, causing stockholders to lose some or all of their investment.
• The sale of material amounts of common stock could encourage short sales and depress the price.
• Stockholder ownership of common stock may be diluted if common stock is sold in a capital raising transaction or shares are issued in a future acquisition.
• Anti-takeover provisions could inhibit a change in control or management that stockholders consider favorable.
• Stockholders must rely on stock appreciation for any return on investment as dividends are not expected in the foreseeable future.

Future Outlook

The company expects to initiate a clinical trial for its novel dual energy platform (PFA with Advanced RFA) in the coming year. Patient follow-up for the LeAAPS trial and site initiation and enrollment for the BoxX-NoAF trial are ongoing. The company plans to present long-term patient follow-up results from multiple studies at 2026 meetings and is conducting analyses for future development or label expansions. Substantial expenditures are anticipated for product development and commercialization. Management believes current cash and credit facilities will be sufficient for anticipated cash needs for at least the next twelve months, while remaining opportunistic regarding acquisitions.

Management Comments

• "At AtriCure, we are proud to be part of a remarkable organization—one that is All Ways Innovating to improve the lives of patients affected by atrial fibrillation and post-surgical pain." Mike Carrel, Chief Executive Officer
• "Our work impacts patients, health care providers, business partners, colleagues, and communities around the world. We are Mission Driven to do business the right way, every day." Mike Carrel, Chief Executive Officer
• "Our Code of Conduct serves as a guide to help each of us—employees, officers, and directors—make ethical, responsible decisions in everything we do. It reflects our commitment to integrity, accountability, and trust." Mike Carrel, Chief Executive Officer
• "If you have questions, concerns, or are unsure about what’s right, we urge you to speak up. The Global Compliance Department is here to support you, and we do not tolerate retaliation against anyone who raises a concern in good faith." Mike Carrel, Chief Executive Officer
• "Our reputation for excellence is built one decision at a time. Together, let’s continue to lead with integrity, inspire trust, and uphold the high standards that define AtriCure. Our future is bright—and it depends on all of us." Mike Carrel, Chief Executive Officer
• "We believe that our current cash and cash equivalents, along with the cash we expect to generate or use for operations or access via our Credit Agreement, will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next twelve months." Management

Industry Context

StockSavvy.ai notes that AtriCure operates in a growing market for Afib treatment and pain management, driven by an aging global population and increasing awareness of Afib. The decline in minimally invasive ablation sales, attributed to the adoption of PFA catheters by electrophysiologists, highlights a competitive shift within the Afib treatment landscape, where AtriCure is actively developing its own PFA technology to remain competitive. The focus on non-opioid pain management solutions like Cryo Nerve Block aligns with broader healthcare trends to reduce opioid dependency.

Comparison to Industry Standards

• AtriCure holds a unique position with the only medical devices approved by FDA for treating long-standing persistent Afib: the Isolator Synergy Ablation and the EPi-Sense System, differentiating it from competitors like Medtronic, plc, and other catheter-based ablation providers.
• The CONVERGE trial demonstrated superior efficacy for AtriCure's hybrid therapy arm compared to endocardial catheter ablation alone for long-standing persistent Afib, showing a 29% absolute difference in efficacy at 12 months (78% relative improvement) and 35% at 18 months (110% relative improvement), significantly outperforming the less than one-third success rate of catheter ablation alone for this patient group.
• The ICE-AFIB clinical trial reported 70% freedom from atrial fibrillation/flutter/tachycardia from 6 through 12 months, with a 30-day major adverse event rate of 9.3%, with all events unrelated to surgical ablation/device.
• The CEASE-AF trial demonstrated superior freedom from atrial arrhythmias for staged hybrid ablation compared to endocardial catheter ablation, with statistically similar safety rates and fewer interventions through three years.
• AtriClip devices are the most widely sold LAA management devices worldwide, having treated more than 750,000 patients, indicating strong market leadership.
• The company's voluntary employee turnover rate consistently remains at or below 10%, which is lower than the industry average for medical device companies, reflecting strong employee satisfaction and retention.
• AtriCure has been recognized as a Top Workplace ten times in the past eleven years and a Great Place to Work internationally for four consecutive years, suggesting a highly positive internal culture compared to general corporate benchmarks.
• Recognition by Fast Company, Inc. in 2024 for offering the best opportunities for women innovators highlights a commitment to diversity and innovation that sets it apart in the MedTech sector.

Corporate Governance

Legal Proceedings

• On February 7, 2025, a complaint was filed in the Delaware Court of Chancery by the representative for former securityholders of SentreHEART, Inc., naming AtriCure as a defendant.
• On May 23, 2025, a first amended complaint was filed, alleging breach of contract and breach of the implied covenant of good faith and fair dealing.
• The complaint stems from AtriCure's alleged failure to use commercially reasonable efforts to obtain premarket approval from FDA for the LARIAT System.
• The amended complaint seeks damages up to $260,000 thousand plus interest, representing the original PMA and CPT reimbursement milestones.
• AtriCure intends to vigorously defend this claim and has not recognized a liability as any potential loss is not currently probable or reasonably estimable.
• During the first quarter of 2023, AtriCure entered into a legal settlement of $7,500 thousand in connection with claims filed against a competitor, recognizing a gain.

Stakeholder Impact

• Shareholders: Impacted by strong revenue growth and narrowing net losses, but face potential dilution from future capital raises and significant financial exposure from the SentreHEART legal proceeding seeking up to $260 million in damages. No dividends are expected.
• Patients: Benefit from continued product innovation, expanded treatment options for Afib and post-surgical pain, and ongoing clinical trials aimed at improving outcomes and preventing complications.
• Healthcare Providers (HCPs): Gain access to new and enhanced medical devices and benefit from extensive training and education programs. However, shifts in treatment paradigms, such as the adoption of PFA catheters, may influence product usage.
• Employees: Benefit from a strong company culture, low voluntary turnover, and investments in talent development and diversity initiatives. Potential for stock-based compensation is tied to company performance.
• Business Partners/Suppliers: Subject to the company's ethical and quality standards, with reliance on single-source suppliers posing potential supply chain risks.
• Regulatory Authorities: Engaged through ongoing clinical trials and regulatory submissions for product approvals and clearances, ensuring product safety and efficacy.

Next Steps

• Initiate a clinical trial for the novel dual energy platform (Pulsed Field Ablation with Advanced Radiofrequency Ablation) in the coming year.
• Continue patient follow-up for the LeAAPS IDE clinical trial.
• Continue site initiation and patient enrollment for the BoxX-NoAF IDE trial.
• Present long-term patient follow-up results from multiple studies at 2026 meetings.
• Conduct analyses of additional trial data for publication, future development activities, or possible evaluation of label expansions.
• Continue to invest in facilities to support growth, including the expansion of the Mason Manufacturing Building.
• Actively work to pursue market access and new reimbursement for therapies in certain international geographies.
• Evaluate acquisition opportunities based on product innovation, clinical differentiation, and strategic/financial criteria.
• Continue to evaluate, modify, and enhance internal processes to increase employee engagement, productivity, and efficiency, and to recruit new employees.
• Continue to improve operational and management controls, reporting and information technology systems, and financial internal control procedures.
• Monitor the impact of inflation on cost of revenue and operating expenses.
• Evaluate the impact of adopting new FASB ASUs (2024-03, 2025-06, 2025-10) on consolidated financial statements and disclosures.

Key Dates

Recommendation

AtriCure demonstrated impressive revenue growth and a substantial reduction in net losses, indicating positive operational momentum and market acceptance of its core products. Strategic investments in clinical trials and new product development, including the promising dual energy platform, position the company for future growth. However, the persistent net losses, the decline in minimally invasive ablation sales due to competitive pressures, and the material legal claim seeking $260 million in damages introduce considerable financial uncertainty and risk. A "Hold" recommendation is appropriate as investors should monitor the company's path to sustained profitability and the resolution of the legal proceedings before making more aggressive investment decisions.

Keywords

Atrial Fibrillation, Left Atrial Appendage Management, Post-operative Pain Management, Surgical Ablation, Medical Devices, Cryo Nerve Block, Cardiac Surgery, Thoracic Surgery, Amputation Pain, FDA Approval, Clinical Trials, EPi-Sense System, AtriClip System, Isolator Synergy Ablation System, Hybrid AF Therapy, Pulsed Field Ablation, Financial Results, SEC Filing, Healthcare Technology